BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alrizomadlin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Alrizomadlin\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05701306-2887@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Alrizomadlin: Phase 1/2 readout est. (NCT05701306)
DESCRIPTION:Alrizomadlin\, phase 1/2.\nStudy: APG-115 Alone or in Combinati
 on With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors\
 nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/alrizomadlin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05701306
URL:https://assetmemo.bio/drug/alrizomadlin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06735820-2887@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Alrizomadlin: Phase 1/2 readout est. (NCT06735820)
DESCRIPTION:Alrizomadlin\, phase 1/2.\nStudy: Early Phase Study Evaluating 
 MEK and MDM2 Inhibition in Patients With NF1 and MPNST\nEstimated primary 
 completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/alrizomadlin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06735820
URL:https://assetmemo.bio/drug/alrizomadlin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
